Regulatory consideration and pathways for vaccine development

Vaccines are biological products that persuade the immune response against (infectious and noninfectious) diseases upon consequent introduction to a pathogen. Traditionally, vaccines are produced by pathogen attenuation or chemical inactivation; hence, development took years (15–20 years) to launch the vaccines into the market for clinical use. However, with the advent of modern technologies such as recombinant DNA technology, proteomics, genomics, transcriptomics, and artificial intelligence have reduced vaccine development duration. Preformulation and formulation development were performed for physiochemical property optimization and vector and targeted disease selection at the preclinical stage. This has been applied to mRNA-, DNA-, peptide-, protein-, and organism-based vaccines, which are reaching the market within a short period of time. COVID-19 is a good example for the quick development of vaccines and emergency approval with all regulatory considerations and pathways required for the purity, potency, safety, and effectiveness of vaccines for human use. Vaccine licensing and pre-IND and IND applications are required for clinical development to establish vaccine safety and efficacy. Biologic license application in electronic format produced before the Centre for Biologics Evaluation and Research of the US FDA. The Code of Federal Regulations, Title 21, Part 600, which is responsible for the publication of licensing regulations, entails vaccine safety and purity. Moreover, vaccines are available before approvals through recognized paths, that is, Emergency Use Authorization and accelerated approval based on surrogate markers of effectiveness. Phase IV for postmarketing trials to collect large-scale data for safety is controlled by the FDA Vaccine Adverse Event Reporting System and Centres for Disease Control and Prevention.